Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 6830-6840

  Zwicker, Jeffrey I ^a   Liebman, Howard A ^c   Neuberg, Donna ^b   Lacroix, Romaric ^a   Bauer, Kenneth A ^a   Furie, Barbara C ^a   Furie, Bruce ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOPLASTIN;

ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; MALE; PANCREAS CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK FACTOR; THROMBOCYTE POOR PLASMA; VENOUS THROMBOEMBOLISM;

AGED; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; THROMBOPLASTIN; THROMBOSIS; TUMOR MARKERS, BIOLOGICAL; VENOUS THROMBOEMBOLISM;

EID: 72549102588     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0371     Document Type: Article

References (45)

1. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
2. Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995;74:278-281
3. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost 1998;24:93-109.
4. Arkel YS. Thrombosis and cancer. Semin Oncol 2000;27:362-374
5. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102:V215-24.
6. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124:58-68S.
7. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004;5:655-663
8. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723-1729 (Pubitemid 47443881)
9. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815
10. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4:529-535
11. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291
12. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-1201
13. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981;67:1665-1671
14. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400.
15. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71:10-16
16. Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 1987;5:1998-2003. (Pubitemid 18010161)
17. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 1997;33:50-55
18. Johnson MJ, Walker ID, Sproule MW, Conkie J. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 1999;21:51-54 (Pubitemid 29143409)
19. Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001;86:828-833 (Pubitemid 32834193)
20. Sallah S, Husain A, Sigounas V, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004;10:7238-7243 (Pubitemid 39487710)
21. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2:2107-2114
22. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-949
23. Giesen PL, Rauch U, Bohrmann B, et al. Bloodborne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-2315 (Pubitemid 29117911)
24. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-1598 (Pubitemid 36682554)
25. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001;112:81-90. (Pubitemid 32151154)
26. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683 (Pubitemid 37193612)
27. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999;104:93-102.
28. Chironi G, Simon A, Hugel B, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006;26:2775-2780 (Pubitemid 44777296)
29. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007;5:520-527
30. Hron G, Kollars M, Weber H, et al. Tissue factor- positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007;97:119-123
31. Zwicker JI, Furie BC, Kos C, LaRocca T, Bauer KA, Furie B. Trousseau's syndrome revisited: tissue factor-bearing microparticles in pancreatic cancer [abstract 259]. Blood 2005;:106.
32. Hercher M, Mueller W, Shapiro HM. Detection and discrimination of individual viruses by flowcytometry. J Histochem Cytochem 1979;27:350-352 (Pubitemid 9127897)
33. Shapiro HM. Practical flow cytometry. 4th ed. New York: Wiley-Liss; 2003.
34. Dvorak HF, Quay SC, Orenstein NS, et al. Tumor shedding and coagulation. Science 1981;212:923-924
35. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-651
36. Levi E, Klimstra DS, Andea A, Basturk O, Adsay NV. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004;57:456-462
37. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-2346 (Pubitemid 350100757)
38. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-2829
39. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008;6:1983-1985
40. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007;13:2870-2875 (Pubitemid 46849560)
41. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008;6:1517-1524
42. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-131
43. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of lowdose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063-4069 (Pubitemid 46211311)
44. Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a doubleblind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-296 (Pubitemid 43160120)
45. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057-4062